[go: up one dir, main page]

ATE414776T1 - Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten - Google Patents

Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten

Info

Publication number
ATE414776T1
ATE414776T1 AT02714638T AT02714638T ATE414776T1 AT E414776 T1 ATE414776 T1 AT E414776T1 AT 02714638 T AT02714638 T AT 02714638T AT 02714638 T AT02714638 T AT 02714638T AT E414776 T1 ATE414776 T1 AT E414776T1
Authority
AT
Austria
Prior art keywords
cancer
fusion proteins
autoimmune diseases
specific treatment
novel therapeutic
Prior art date
Application number
AT02714638T
Other languages
English (en)
Inventor
Mathieu Noteborn
Johan Renes
Ying-Hui Zhang
Original Assignee
Leadd Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadd Bv filed Critical Leadd Bv
Application granted granted Critical
Publication of ATE414776T1 publication Critical patent/ATE414776T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02714638T 2001-03-30 2002-03-28 Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten ATE414776T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28022901P 2001-03-30 2001-03-30

Publications (1)

Publication Number Publication Date
ATE414776T1 true ATE414776T1 (de) 2008-12-15

Family

ID=23072205

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02714638T ATE414776T1 (de) 2001-03-30 2002-03-28 Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten

Country Status (9)

Country Link
US (1) US20020176860A1 (de)
EP (1) EP1377667B1 (de)
AT (1) ATE414776T1 (de)
AU (1) AU2002246455A1 (de)
DE (1) DE60229924D1 (de)
DK (1) DK1377667T3 (de)
ES (1) ES2321485T3 (de)
PT (1) PT1377667E (de)
WO (1) WO2002079222A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101875688B (zh) * 2010-02-10 2013-04-17 赵洪礼 重组肿瘤特异性凋亡因子制备方法中的叶酸化修饰步骤及其制品的应用
CN101921820B (zh) * 2010-02-10 2013-03-27 赵洪礼 具有活性重组肿瘤特异性凋亡因子的制备方法及其制品的应用
CA2822938A1 (en) 2010-12-27 2012-07-05 Apo-T B.V. A polypeptide that binds aberrant cells and induces apoptosis
EP3388451A1 (de) 2011-09-29 2018-10-17 Apo-T B.V. Multispezifische bindungsmoleküle zum targeting von aberranter zellen
JP2015504895A (ja) 2012-01-13 2015-02-16 エーピーオー‐ティー ビー．ヴイ． 毒性部分を備える異常細胞拘束性免疫グロブリン

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188832A1 (de) * 2000-09-08 2002-03-20 Leadd B.V. Verfahren zur Ablieferung der Tumor-spezifischen Apoptosis-auslösenden Aktivität von Apoptin
EP0878546A1 (de) * 1997-04-15 1998-11-18 Leadd B.V. Genabgabe-Vehikel die das Apoptosis VP2 inducierendes Protein, und/oder Apoptin exprimiert
WO1996041191A1 (en) * 1995-06-07 1996-12-19 Aesculaap B.V. Methods and uses for apoptin
CZ299874B6 (cs) * 1997-08-12 2008-12-17 Leadd B. V. Zpusob urcení transformacní schopnosti cinidel, zpusob urcení predispozice bunky, zpusob zjištení genové mutace, použití nukleové kyseliny kódující apoptin a diagnostická testovací souprava
EP1143994B1 (de) * 1999-01-11 2003-07-02 Leadd B.V. Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
EP1186665A1 (de) * 2000-09-08 2002-03-13 Leadd B.V. Verfahren zur Ablieferung der Tumor-spezifischen Apoptosis-auslösenden Aktivität von Apoptin
WO2002085305A2 (en) * 2001-04-24 2002-10-31 Washington University Compositions and methods for inducing cancer cell death

Also Published As

Publication number Publication date
ES2321485T3 (es) 2009-06-08
AU2002246455A1 (en) 2002-10-15
DK1377667T3 (da) 2009-03-30
EP1377667A2 (de) 2004-01-07
WO2002079222A3 (en) 2003-05-08
EP1377667B1 (de) 2008-11-19
WO2002079222A2 (en) 2002-10-10
US20020176860A1 (en) 2002-11-28
PT1377667E (pt) 2009-03-13
DE60229924D1 (de) 2009-01-02

Similar Documents

Publication Publication Date Title
EP1194164B8 (de) Prion protein peptide und deren verwendung
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
ATE314095T1 (de) Virusähnliche partikel zur induktion von autoantikörpern
TR200102191T2 (tr) HER-2/neu füzyon proteinleri.
CY1108489T1 (el) Παραγωγη τετρασθενων αντισωματων
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
ATE409181T1 (de) Proteomimetische verbindungen und verfahren
DE59905954D1 (de) Dialkylfumarate zur behandlung von autoimmunerkrankungen
ATE281180T1 (de) Pharmazeutische zusammensetzung enthaltend nicht- mhc-abhängige t-zellen/nk-zellen und mhc- abhängige zellen zur behandlung von tumoren
DE602004001857D1 (de) Thienopyrimidindione und deren verwendung bei der modulierung von autoimmunerkrankungen
ATE362925T1 (de) Zusammensetungen und verfahren zur modulation von apoptose in cellen, die proteine der bc1-2- familie exprimieren
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
DE60204224D1 (de) Verwendung bestimmter substituierter pyrrolidone wie z.b. piracetam bei der behandlung von viralen und anderen erkrankungen
DE60215649D1 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
DE60229924D1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
GB0004576D0 (en) Proteins
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
DE69835828D1 (de) Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression
DE60143074D1 (de) Immunmodulation mit rezeptorinduziertem tod durch apoptosis
ATE505538T1 (de) Dna-vektoren
ATE528392T1 (de) Neues protein und dessen dns

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1377667

Country of ref document: EP

REN Ceased due to non-payment of the annual fee